Endocrine Abstracts

Background: One of the basic genetic factors that impact on development of diabetic nephropathy is enhanced expression of vascular endothelial growth factor (VEGF).

Objective: To study association between VEGF polymorphism +405 G/C and early stage of chronic kidney disease (CKD) in patients with impaired glycemic states.

Materials and methods: 73 included patients were divided into three groups: group 1–26 patients with prediabetes (impaired fasting glucose and impaired glucose tolerance), group 2–28 patients with type 2 diabetes (T2D) and group 3–20 almost healthy person. To determine the stage of CKD we calculated glomerular filtration rate (GFR; ml/min per 1.73 m²) by Cockcroft–Gault equation. Patients with CKD3–5 were excluded. We estimated distribution of VEGF genotype in study groups.

Results and discussion: Distribution of VEGF genotype and CKD stage are presented in Table 1.

We revealed that VEGF +405 G/C polymorphism in patients with T2D was associated with decreased GFR (CKD2): 84.28 (82.59; 87.38) compared to 106.07 (89.63; 136.91) in control group (P=0.02). We didn’t reveal statistical significance in groups with VEGF polymorphism C/C and G/G. It can be assumed that polymorphism C/C and G/G possess nephroprotective action. Increased glucose levels promote activation of VEGF +405 G/C polymorphism.

Conclusion: VEGF +405 G/C polymorphism was associated with Stage of CKD in patients with T2D and was not associated with GFR impairment in patients with prediabetes.